We improve the lives of people with chronic conditions by improving pharmaceutical policies to optimise medical treatments, facilitate equal access to medications, and foster transparency.
Are pharmaceutical policies in Australia based on evidence or influence? We answer this question collaborating with consumers and medical professionals to research on policy, evidence and influence related to drug therapies for obesity, diabetes, cardiovascular disease, cancer, ageing and mental health.
Our goal is to inform policy debates with high quality evidence in order to develop solutions for optimizing treatment for patients affected by chronic disease. We give evidence-based responses to controversial aspects of drug-therapies such as: influence on health consumers and medical professionals by the pharmaceuticals industry, equal access to medications, and over-prescribing.
• Industry sponsorship of patient groups: A series of studies on funding of health consumer organisations in Australia and internationally, including: funding patterns, transparency, conflicts of interest.
• Commercial influences on professional practice: Creation of publicly available, usable databases of industry funding of health professionals in Australia. See the work already done so far at the Charles Perkins Centre.
• Effective warnings for clinicians and the public on harmful effects of medicines: A comparison of the Therapeutic Goods Administration (TGA)’s safety advisories on medicines with those of US, Canadian and European regulators over the last decade.
The project node works to improve treatment, with or without drugs, for patients affected by chronic disease, as well as increase transparency in pharmaceutical policies. Examples include: analysis of the role of drug therapies for obesity, evaluation of the increased access to insulin analogues in low-income countries, examination of the warnings by regulators about newly discovered harmful effects of medicines.
Advisory committee members